


Indonesian J. Pharm.  
Volume 28 Issue 4 (2017)  
October-December



ISSN : 2338-9427  
Formerly ISSN : 0126-1037

# Indonesian Journal of Pharmacy (Indonesian J. Pharm.)

Accredited by DGHE (DIKTI) No. 58/DIKTI/Kep/2013



STT NO. 1652/SK/DITJEN PPG/SST/1990

Faculty of Pharmacy  
Universitas Gadjah Mada



# Indonesian Journal of Pharmacy



Home About Login Register Search Current Archives Announcements Indexing & Abstracting Journal History Contact

Home > Archives > Vol 28 No 4, 2017

Vol 28 No 4, 2017

## Table of Contents

### Articles

**The employment of UV-spectroscopy combined with multivariate calibration for analysis of paracetamol, Propyphenazone and caffeine**

*Abdul Rohman, Arief Dzulfianto, Florentinus Dika Octa Riswanto*

DOI:10.14499/indonesianjpharm28iss4pp191 | Abstract view:556 | PDF download:128

**Effect of Lipid Ratio of Stearic Acid and Oleic Acid on Characteristics of Nanostructure Lipid Carrier (NLC) System of Diethylammonium Diclofenac**

*Esti Hendradi, Noorma Rosita, Erwinda Rahmadhanniar*

DOI:10.14499/indonesianjpharm28iss4pp198 | Abstract view:202 | PDF download:125

**Population-Based Approach to Analyze Sparse Sampling Data in Biopharmaceutics and Pharmacokinetics using Monolix and NONMEM**

*Akhmad Kharis Nugroho, Arief Rahman Hakim, Lukman Hakim*

DOI:10.14499/indonesianjpharm28iss4pp205 | Abstract view:471 | PDF download:123

**The Influence of Medication Days' Supply on Adherence and Cost of Hypertensive Patients at Primary Health Care Centre**

*Mufarrihah Mufarrihah, Catur Dian Setiawan, Nurul Wathaniah, Atikah Rahmaniah, Primanda Ayu Maharani, Azzahroh Sifa' Lailiyah Mahmudah, Gusti Noorizka Veronika Achmad*

DOI:10.14499/indonesianjpharm28iss4pp213 | Abstract view:449 | PDF download:124

**Review of Insulin Therapy In Type 2 Diabetes Mellitus Ambulatory Patients**

*Budi Suprapti, Nia Widyasari, Mahardian Rahmadi, Cahyo Wibisono*

DOI:10.14499/indonesianjpharm28iss4pp221 | Abstract view:708 | PDF download:129

**Provision of Patient Medication Counseling Service In A Tertiary-Care Eye Hospital In Bandung: A Gap Analysis of Patient's Need, Standard and Service Provider Resources**

*Tomri Hendrayana, Zulfan Zazuli, Genialita Fadhila, Nur Sidik Cahyono*

DOI:10.14499/indonesianjpharm28iss4pp232 | Abstract view:546 | PDF download:117

**Development And Validation Of Stability Indicating RP-HPLC Method For Determination Of Ceritinib**

*Vaibhav Suresh Adhao, J Sharma, M Thakre*

DOI:10.14499/indonesianjpharm28iss4pp241 | Abstract view:195 | PDF download:123

### Indonesian J Pharm indexed by:



Focus & Scope

Author Guideline

Author Fees

Online Submission

Editorial Board

Peer Reviewer

Subscription Form

Screening for Plagiarism

Visitor Statistics

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI



### CITATION ANALYSIS

► SCOPUS

► GOOGLE SCOLAR

### TEMPLATE



### TOOLS



### NOTIFICATIONS

► View

► Subscribe

### USER

Username



# Indonesian Journal of Pharmacy



[Home](#)
[About](#)
[Login](#)
[Register](#)
[Search](#)
[Current](#)
[Archives](#)
[Announcements](#)
[Indexing & Abstracting](#)
[Journal History](#)
[Contact](#)

Home > About the Journal > **People**

## People

### Reviewer

- Dr. Enade Perdana Istyastono, Faculty of Pharmacy, Universitas Sanata Dharma, Indonesia
- Dr. Susi Ari Kristina, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Taha Nazir, Intellectual Consortium of Drug Discovery & Technology Development Inc., 937 Northumberland Ave Saskatoon Saskatchewan S7L3W8 Canada., Canada
- Dr. Gunawan Pamudji Widodo, Faculty of Pharmacy Setia Budi University Surakarta Indonesia, Indonesia
- Dr. Agatha Budi Susiana, Faculty of Pharmacy, Universitas Sanata Dharma, Indonesia
- Dr. Endang Lukitaningsih, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Adam Hermawan, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Uttam Budhathoki, Department of Pharmacy, Kathmandu University, Nepal
- Prof. Dr. Ridwan Amirudin, Faculty of Public Health, Universitas Hasanuddin, Indonesia
- Dr. Ari Sudarmanto, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Dyah Aryani Perwitasari, Faculty of Pharmacy, Universitas Ahmad Dahlan,, Indonesia
- Dr. Arief Nurrochmad, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Prof. Dr. Shufeng Zhou, Department of Pharmaceutical Sciences, University of South Florida Tampa, United States
- Dr. Triana Hadna, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Abdul Wahab, Department of Pharmacy, Kohat University of Science and Technology (KUST), Pakistan
- Dr. Montarat Thavorncharoensap, Faculty of Pharmacy, Department of Pharmacy, Mahidol University, Thailand
- Dr. Mohammed Emamussalehin Choudhury, Department of Pharmacology, Bangladesh Agriculture University, Bangladesh
- Dr. Dipak D Gadade, Shri Bhagwan College of Pharmacy, CIDCO N6, Aurangabad, India
- Dr I Wayan Mudianta, Ganesha University of Education, Bali, Indonesia, Indonesia
- Dr. Muthi Ikawati, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Nining Sugihartini, Faculty of Pharmacy, Universitas Ahmad Dahlan, Indonesia

### Indonesian J Pharm indexed by:



- [Focus & Scope](#)
- [Author Guideline](#)
- [Author Fees](#)
- [Online Submission](#)
- [Editorial Board](#)
- [Peer Reviewer](#)
- [Subscription Form](#)
- [Screening for Plagiarism](#)
- [Visitor Statistics](#)

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI



### CITATION ANALYSIS

- [▶ SCOPUS](#)
- [▶ GOOGLE SCOLAR](#)

### TEMPLATE



### TOOLS



### NOTIFICATIONS

- [▶ View](#)
- [▶ Subscribe](#)

### USER

Username

# Indonesian Journal of Pharmacy



Home About Login Register Search Current Archives Announcements Indexing & Abstracting Journal History Contact

Home > Vol 28 No 4, 2017 > **Suprapti**

## Review of Insulin Therapy In Type 2 Diabetes Mellitus Ambulatory Patients

Budi Suprapti, Nia Widyasari, Mahardian Rahmadi, Cahyo Wibisono

### Abstract

The purposes of this study were to review utilization of insulin therapy in type 2 diabetes mellitus out patients and identify its drug related problems. The data were collected cross-sectionally with purposive sampling method in the period March 2016 until May 2016 in Outpatient Clinic Universitas Airlangga Teaching Hospital Surabaya. The results of 240 patients showed that insulin was used as monotherapy insulin in 2,9% patients; combination 1 insulin & 1-4 OAD in 31,3%; basal bolus therapy 27,9%; combination basal-bolus therapy & 1-3 OAD 43,9%. Based on blood glucose target achievement, only 20,8% of patients achieve the target, 75,1% failed to achieve the target and 4,1% suffered from hypoglycemia. Drug related problems identified adverse drug reaction of antidiabetic therapy such as hypoglycemia (6.7%), nausea (3.8%), bloating (1.3%), increase of flatulency (2.9%) and inappropriate combination (0,4%). In conclusion insulin therapy was complicated and individually, most of the patients still did not reach the target and there was potential drug related problem in this patients group. So that caring from solid inter-professional health collaboration is needed

### Keywords

Diabetes mellitus, insulin, ambulatory patient, DUR, DRP

### Full Text:

PDF

### References

- American Diabetes Association., 2015. Standards of Medical Care in Diabetes: Volume 38 Supplement 1: S1-S83
- Barret, Kim E., Barman, Susan M, Boitano, Scott and Brooks, Heddwen L. 2012. Ganong's Review of Medical Physiology. 24th Edition. New York: The McGraw-Hill Companies.
- Bennett, K., Bhandari., 2015. An overview of diabetic nephropathy: Epidemiology, pathophysiology and treatment. Journal of Diabetes Nursing. Volume 19. No. 2. Pp. 61-67
- Bloomgarden, T, Zachary., 2004. Type 2 Diabetes in the Young: The evolving epidemic. Diabetes Care. Volume 27, No. 4. pp. 998
- Boucher, J., Kleinridders, A., Kahn, C. Ronald., 2014. Insulin Receptor Signaling in Normal and Insulin-Resistant States. Harvard Medical School
- CDC. 2015. Distribution of Age at Diagnosis of Diabetes Among Adult Incident Cases Aged 18-79 Years. Centers for Disease Control and Prevention
- Funk, J.L. 2014. Disorder of The Endocrine Pancreas. In: McPhee.S. J; Hammer G.D. (Eds.), Pathophysiology of Disease an Introduction to Clinical Medicine. 7th ed. : New York : Mc Graw Hill
- Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., Francois, J., 2013. Pharmacologic Management of Type 2 Diabetes. Canadian Journal of Diabetes. 37(2013): S61-S68
- Hundal, R.S., Inzucchi, S.E., 2003. Metformin: New Understandings, New Uses. Leading Article. pp 1800-1889
- IDF Diabetes Atlas. 2013. International Diabetes Federation 6th ed. pp: 19-99
- Inzucchi, S, E., Bergenstal, R.M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., Matthews, D.R., 2015. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient Center Approach. Diabetes Care 2015; 38: 140-149
- Ismail, F., 2004. Current Management of Type 2 Diabetes: Why Thiazolidinediones Should Be the Cornerstone of Therapy. The Journal of Applied Research. Volume. 4, No 3.
- Kennedy & Masharani. 2012. Pancreatic Hormones and Antidiabetic Drugs. In: Basic and Clinical Pharmacology. 12th Edition. New York: The McGraw-Hill Companies, p. 743-765.
- Kirkman M.S., Jones, V.B., Clark, N., Florez, H., Haas, L.B., Halter, J.B., Huang, E.S., Korytkowski, M.T., Munshi, M.N., Odegard, P.S., Pratley, R.E., Swift, C.S., 2012. Diabetes in Older Adults. Diabetes Care, Volume 35. pp. 2650-2655
- Kroon & Williams. 2013. Endocrine Disorders. In: Koda-Kimble & Young's (Eds.). Applied Therapeutics the Clinical Use of Drugs.10th

Focus & Scope

Author Guideline

Author Fees

Online Submission

Editorial Board

Peer Reviewer

Subscription Form

Screening for Plagiarism

Visitor Statistics

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI



### CITATION ANALYSIS

▶ SCOPUS

▶ GOOGLE SCOLAR

### TEMPLATE



### TOOLS



### NOTIFICATIONS

▶ View

▶ Subscribe

### USER

Username



## REVIEW OF INSULIN THERAPY IN TYPE 2 DIABETES MELLITUS AMBULATORY PATIENTS

Budi Suprapti<sup>1,3\*</sup>, Nia Widyasari<sup>1</sup>, Mahardian Rahmadi<sup>1,3</sup>, Cahyo Wibisono<sup>2,3</sup>

<sup>1</sup>Faculty of Pharmacy  
Universitas Airlangga, Jl.  
Dharmawangsa No 4-6,  
Surabaya, Indonesia

<sup>2</sup>Faculty of Medicine  
Universitas Airlangga, Jalan  
Dr. Moestopo, Surabaya,  
Indonesia

<sup>3</sup>Universitas Airlangga  
Teaching Hospital, Jalan  
Mulyorejo, Surabaya,  
Indonesia

Submitted: 11-11-2017

Revised: 25-11-2017

Accepted: 20-12-2017

\*Corresponding author  
Budi Suprapti

Email:  
buidprapti@yahoo.co.id

### ABSTRACT

The purposes of this study were to review utilization of insulin therapy in type 2 diabetes mellitus out patients and identify its Drug Related Problems (DRP). The data were collected cross-sectionally with purposive sampling method in the period March 2016 until May 2016 in Outpatient Clinic of Teaching Hospital Universitas Airlangga Surabaya. The results of 240 patients showed that insulin was used as monotherapy (insulin) in 2.9% patients; combination 1 insulin & 1-4 OAD in 31.3%; basal bolus therapy 27.9%; combination basal-bolus therapy & 1-3 OAD 43.9%. Based on blood glucose target achievement, only 20.8% of patients achieve the target, 75.1% failed to achieve the target and 4.1% suffered from hypoglycemia. DRP identified adverse drug reaction of antidiabetic therapy such as hypoglycemia (6.7%), nausea (3.8%), bloating (1.3%), increase of flatulency (2.9%) and inappropriate combination (0.4%) were observed. In conclusion insulin therapy was complicated and individually, most of the patients still did not achieve the target and there was potential DRP in this patients group. Therefore caring from solid inter-professional health collaboration is needed.

**Key words:** Diabetes mellitus, insulin, ambulatory patient, DRP

### INTRODUCTION

Diabetes Mellitus (DM) is one of the major worldwide health problems, the incidence of DM has exhibited epidemic conditions (Barret *et al.*, 2012). Global study data showed that DM patients in 2013 has reached 382 million people and is estimated the increase to 592 million by 2035. In 2012, 5.1 million people in the age of 20 to 79 died of diabetes, which is equivalent to one death every six seconds is caused by diabetes and nearly half (48%) of them are under 60 years old (IDF, 2013). In 2013, diabetic patients in Indonesia had reached 8.5 million people (IDF, 2013), whereas in East Java, it was estimated up to 2.1% (RIKESDAS, 2013).

Type 2 DM requires intensive therapy management to prevent its progressivity and complications. The principal of management therapy in Type 2 DM included non-drug therapy-healthy lifestyle and drug therapy i.e. oral antidiabetic (OAD) either single or in combination with insulin (Suastika *et al.*, 2011). When blood glucose levels remain uncontrolled, the OAD administration is stopped and the therapy is switched to

insulin intensively (Ndraha, 2014). Early initiation of insulin therapy shows better clinical outcomes primarily related to glucotoxicity (Suastika *et al.*, 2011). In addition, according to a study by UKPDS 35, the early insulin therapy in Type 2 DM intensively showed a decrease in morbidity or mortality (Soewondo *et al.*, 2010).

Initiation of insulin therapy in patients with type 2 diabetes could be conducted in patients who fail oral antidiabetic therapy (OAD), has poor blood glucose control (A1C > 7.5% or fasting blood glucose >250mg/dL), with history of pancreatomy or pancreatic dysfunction, history of fluctuations in blood glucose levels, history of ketoacidosis, and experienced of DM over 10 years (Rismayanthi, 2010). In addition, insulin therapy is also given to patients with type 2 DM who have some comorbid such as chronic hepatitis, pulmonary tuberculosis, fractures, cancer, cellulitis/gangrene, graves' disease and severe hepatic disorders (Pranoto, 2012). This study aims to review the use of insulin therapy in type 2 DM patients and identification of drug-related problems in these patients.



## MATERIAL AND METHODS

This is an observational and cross-sectional study conducted at the Out-patient Clinic Universitas Airlangga Teaching Hospital in Surabaya, Indonesia. Inclusion criteria were Type 2 DM patients undergoing therapy using insulin or insulin-OAD (Oral Anti Diabetic) combination. The data were collected from March to May 2016. The sampling was obtained by purposive sampling method until the sample number was fulfilling. Descriptive analysis was conducted for the patient's insulin therapy profile, achievement of blood sugar target and problems that are related to anti-diabetic.

## RESULT AND DISCUSSION

From 240 patients obtained there were 127 (52.9%) female patients which was higher than male patients, 113 (47.1%). This aligned with the International Diabetes Federation data that shows the prevalence of DM patients in Indonesia is higher in women, that is 57.73% (IDF, 2013). The higher prevalence of Type 2 DM patients in women is associated with lower physical activity and more obesity conditions experienced by women (WHO, 2016).

Based on age distribution, it shows that more patients in the age of the 45-54 years there were (25.8%) and 55-64 years (41.2%) (Table I). This is in accordance with the research conducted by the Center for Disease Control and Prevention, which shows that most people with Type 2 DM are in the age range of 45-64 years (CDC, 2015), where at age > 45 years the insulin resistance increase and impaired function of pancreatic cells (Kyung *et al.*, 2016). The impaired of pancreatic cell function causes a decrease in the capacity of proliferative islet cells resulting in a decrease in insulin production (Kirkman *et al.*, 2012). However, in this study there were 7.5% of patients in the age of <45 years and there was one patient (0.4%) at the age of 25 years old. Research conducted by the Ministry of Health of the Republic of Indonesia in 2013 showed that 9.90% of patients with Type 2 DM is at the age <45 years (RISKESDAS, 2013). This indicates that incidence of Type 2 DM is increasing among young people. Lifestyle and obesity is the main factors suspected to be the

cause of Type 2 DM. In addition, genetic factors, gestational diabetes and lack of physical activity during childhood and adolescence lead to an increase in insulin resistance that triggers the onset of Type 2 DM among young people (Bloomgarden, 2004).

In Type 2 DM patients may be accompanied by various microvascular and macrovascular and comorbid complications (Table I). In this study the most complication experienced was nephropathy 24.2% and comorbid was hypertension 62.9%. Diabetic nephropathy is a microvascular complication characterized by hyperfiltration of the glomerular basement membrane (Funk, 2014). The pathogenesis of diabetic nephropathy may be an increase in AGEs product that causes damage to the renal glomerulus. In addition, polyol pathway increases sorbitol and decreases inositol levels causing impaired basement membrane osmolarity (Bennett and Bhardari, 2015). While, in this study 62.9% patients with hypertension. Hypertension is a risk factor for DM (ADA, 2015), in the other hand hypertension is one complication of DM. A hyperglycemia conditions cause glucose to react non-enzymatically with free amino acids of the body membrane, produce AGEs product that will cause damage the organs and blood vessel network as well as the formation of arteriosclerosis that causes narrowing of artery walls (Funk, 2014).

According to PERKENI, at the beginning of therapy Type 2 DM can be used OAD monotherapy. If blood glucose has not been controlled with OAD monotherapy use a combination of 2 OAD with a different mechanism. If on 2 OAD combinations blood glucose still uncontrollable a combination of 3 OAD or a combination of 2 OAD can be used together with basal insulin. If on this combination blood glucose remains uncontrolled, then the OAD is stopped and the therapy switches to insulin intensively (PERKENI, 2011). The European Association for the Study of Diabetes (EASD) recommends the more aggressive type 2 DM therapy that after the first step with lifestyle intervention and metformin is unsuccessful, the next step can be started by administering insulin. Early insulin initiation provides better glycemic

Tabel 1. Characteristic of Type 2 DM Patients in Out Patients Clinic Universitas Airlangga Teaching Hospital Surabaya Indonesia

No.	Characteristic	Number of patients (%)	
1	Gender	Male	113 (47,1)
		Female	127 (52,9)
2	Age (year)	25-34	1 (0,4)
		35-44	18 (7,7)
		45-54	62 (25,8)
		55-64	99 (41,2)
		65-74	46 (19,2)
		>75	14 (5,8)
3	Complication	Nephropathy	58 (24,2)
		Neuropathy	20 (8,3)
		Retinopathy	1 (0,4)
		Coronary Artery Disease	5 (2,1)
		Stroke	4 (1,7)
		Ulcer Pedis	2 (0,8)
		Gangrene	2 (0,8)
		Chronic Kidney Disease	4 (1,7)
4	Comorbid	Hypertension*	151 (62,9)
		Dyslipidemia	102 (42,5)
		Dyspepsia	16 (6,7)
		Hypertoroid	1 (0,4)
		Hyperuricemia	31 (12,9)
		Osteoarthritis	9 (3,7)
		Heart failure	3 (1,2)
		Hepatic Cirrhosis	1 (0,4)
		Ascites	1(0,4)
		<i>Frozen shoulder</i>	1 (0,4)
		Acute Respiratory infection	5 (2,1)
		Anemia	1 (0,4)
		Cholelithiasis ( <i>Batu empedu</i> )	4 (1,7)
		<i>Low Back Pain</i> (LBP)	1(0,4)
		Benign Prostate Hyperplasia (BPH)	3 (1,2)
Asthma	2 (.8)		
Vertigo, Cephalgia	3 (1,2)		

Note: A patient could have more than one complication and comorbid; Percentage to total patient (240 patient); (\*) Hypertension not known it is DM complication or comorbid. So in this study HT classified into comorbid.

control, improves HbA1C and inhibits the progressivity of decreased pancreatic  $\beta$  cell function (Meneghini, 2009; Inzucchi *et al.*, 2015). In addition, according to a study by UKPDS 35, the use of early insulin therapy in Type 2 DM intensively showed decreased morbidity or mortality (Soewondo *et al.*, 2010). The profiles of antidiabetic, insulin and OAD use were shown in Figure 1, single insulin therapy (2.9%), a combination of 1 insulin and

OAD (31.3%), basal-bolus combination (27.9%), and combination basal bolus insulin-OAD (37.9%).

The types of antidiabetic used were rapid-acting insulin (aspart, glulisine), long-acting insulin (glargine, detemir) and mixed insulin (70/30 protamine aspart/aspart and 75/25 protamine lispro/lispro) subcutaneously, and sulfonylureas, biguanides, thiazolidinedione and  $\alpha$ -glucosidase inhibitors orally (Table II).






Figure 1. Profile of antidiabetic therapy in out patients clinic universitas

Tabel II. Type of antidiabetes used in in out patients clinic Universitas Airlangga Teaching Hospital Surabaya Therapy

Class	Name	Frequency	Total patients in each class (%)
<b>Insulin</b>			
Rapid-acting	Aspart	81 (33.75)	100 (41.7)
	Glulisine	19 (7.92)	
Long-acting	Glargine	105 (43.75)	174 (72.5)
	Detemir	69 (28.75)	
Mixed	- 70/30 Protamine Aspart/ Aspart	58 (24.17)	62 (25.8)
	- 75/25 Protamine Lispro/ Lispro	4 (1.67)	
<b>OAD</b>			
Biguanida	Metformin	102 (42.50)	102 (42.5)
Sulfonilurea	Glimepirid	70 (29.17)	89 (37.1)
	Gliclazid	10 (4.17)	
	Glikuidon	9 (3.75)	
Tiazolidinedione	Pioglitazone	17 (7.08)	17 (7.1)
$\alpha$ -glukosidase inhibitor	Acarbose	49 (20.42)	49 (20.4)

Note : A Patients could get more than one antidiabetes; Percentage to total patient (240 patient)

Long-acting insulin is most widely used, 72.50% of the total patient. The use of long-acting insulin in patients with Type 2 DM is to cover basal insulin needs (Schwinghammer, 2015). The most widely used long-acting insulin is glargine, 43.75%, an insulin analog that has a long acting and peakless. Insulin glargine has a slow onset of action (1-1.5h) and give maximum effect after 4-6h, the activity is maintained for 11-24h or more. Insulin glargine is a clear liquid insulin with a pH of 4, after subcutaneous injection will form micro-precipitation in so that release slowly (Schwinghammer, 2015).

Another long-acting insulin applied is detemir. Detemir insulin has an onset of action 1-2h and a duration of action about 24h (Kennedy and Masharani, 2015). In detemir insulin, the C14 fatty acids are bound to albumin, causes slow release (Schwinghammer, 2015). Administration long-acting insulin can be given in the morning or evening. In this study long-acting insulin 79.89% was administered at night. The use of basal insulin at night can significantly reduce the production of basal glucose hepar in order to provide better glycemic control (Pranoto, 2012).



Table III. Dose and frequency of insulin administration

Drug Name	Insulin Dose	Frequency
Aspart	4-26U	3x
Glulisine	5-32U	3x
Glargine	6-50U	1x
Detemir	6-44U	1x
70/30 Protamine Aspart/Aspart	(6-30)-0-(6-28)U	2x
	(30-34)-10-(28-30)U	3x
75/25 Protamine Lispro/Lispro	(12-24)-0-(10-20)U	2x

Table IV. Time administration of long acting insulin

Type of Long Acting Insulin	Time of Administration	
	Morning (%)	Night (%)
Glargine	19	86
Detemir	16	53
<b>Total</b>	<b>35 (20.1)</b>	<b>139 (79.9)</b>

Note: Percentage of total patient who is got glargine or detemir (174 patient)

From 240 patients, 41.7% received rapid insulin therapy. The administration of rapid-acting insulin aims to fulfill insulin needs at mealtime, because it has a shorter onset and shorter duration of action that mimics normal endogenous insulin secretion (Kennedy and Masharani, 2015). The most widely used type of rapid-acting insulin was aspart insulin 33.8%. Aspart insulin is an insulin analogous with the replacement of the B28 amino acid structure with aspartic acid (Tanyolac *et al.*, 2010). This structural change causes rapid dissociation into monomer form when injected subcutaneously. The onset of action of insulin aspart is 5-15min with a duration of action of 4-6h. Other rapid-acting insulin used is glulisine insulin 7.9%. Glulisine insulin is an analogue insulin that replaces B3- amino acid asparagin with lysine and lysine at the B29 position is replaced with glutamic acid. The onset of action glulisine insulin is 15min with a duration of action about 5h (Tanwani, 2011).

Mixed insulin (premixed insulin) contains long-acting insulin and rapid-acting insulin with a certain ratio in a dosage. The advantage of mixed insulin has a prandial and basal glycemic effect at once, thus it can provide longer glycemic control (Pranoto, 2012). Type of mixed insulin used was 70/30

Protamine Aspart/Aspart insulin (24.2%) and 75/25 Protamine Lispro/Lispro insulin (1.7%). Onset of action 70/30 Protamine Aspart/Aspart insulin is 10-20min with a duration of action 15-18h.

According to the American Diabetes Association, the use of insulin in type 2 diabetes can be started with long-acting insulin in the morning or before bedtime with an initial dose of 10U or 0.2U/kgBW (ADA, 2015). Titration was performed base on blood glucose monitoring, by increasing 2U doses every 3 days until fasting blood glucose (FBG) reaches (70-130mg/dL), or it can be increased 4U or more if FBG > 180mg/dL. If there is a hypoglycemia or FBG < 70mg/dL, dose decreased by 2-4U. The addition of rapid-acting insulin may be performed if 2h postprandial blood glucose (2PPBG) is high, the initial dose usually begins with 4U and adjusts 2U every 3 days until blood glucose is within the target range (Nathan, 2009).

The dosage and frequency of insulin (Table III). In this study, the dose of long-acting insulin in the range 6- 50 units and rapid-acting insulin 4-32 units, while the mixed insulin dose is between 6-34 units in the morning and 6-30 units at night.

Table V. Use of Insulin and Insulin-OAD Combination

Type of Regimen	Agent	Number of Patients (%)
<b>Single Insulin</b>	Rapid acting insulin	1 (0.4)
	Long acting insulin	6 (2.5)
	<b>Total</b>	<b>7 (2.9)</b>
<b>Type 1 combination</b> (1 Insulin + 1 OAD)	Long acting insulin + SU	26 (10.7)
	Long acting insulin + Big	1 (0.4)
	Rapid acting insulin + SU	2 (0.8)
<b>Total</b>	<b>29 (12.1)</b>	
<b>Type 2 combination</b> (1 Insulin + 2 OAD)	Long act. Insulin+ AGI+SU	7 (2.9)
	Long act. Insulin+ Big +SU	22 (9.2)
	Long act. Insulin +TZD + SU	3 (1.2)
	Rapid act. Insulin + Big + SU	1 (0.4)
	<b>Total</b>	<b>33 (13.7)</b>
<b>Type 3 combination</b> (1 Insulin + 3 OAD)	Long act. insulin + AGI + SU + Big	11 (4.6)
	Long act. insulin + SU+Big+TZD	1 (0.4)
	<b>Total</b>	<b>12 (5.0)</b>
<b>Type 4 combination</b> (1 Insulin + 4 OAD)	Long act. Insulin + AGI + SU + Big + TZD	1 (0.4)
<b>Total</b>	<b>1 (0.4)</b>	
<b>Type 5 combination</b> (Insulin Basal-Bolus)	Rapid act. Insulin + Long act.insulin	46 (19.2)
	70/30 mix insulin	19 (7.9)
	75/25 mix insulin	2 (0.8)
	<b>Total</b>	<b>67 (27.9)</b>
<b>Type 6 combination</b> (Insulin Basal-Bolus + 1 OAD)	Rapid act. Insulin + long act. Insulin + AGI	5 (2.1)
	Rapid act. Insulin + long act. Insulin + Big	14 (5.8)
	Rapid act. Insulin + long act. Insulin + TZD	5 (2.1)
	70/30 Mix insulin + AGI	8 (3.3)
	70/30 Mix insulin + SU	2 (0.8)
	70/30 Mix insulin + Big	13 (5.4)
	70/30 Mix insulin + TZD	3 (1.2)
	75/25 Mix insulin + Big	1 (0.4)
	<b>Total</b>	<b>61 (25.42)</b>
	<b>Type 7 combination</b> (Insulin Basal-Bolus + 2 OAD)	Rapid act. Insulin + long act. Insulin + AGI + Big
Rapid act. Insulin + long act. Insulin + SU + Big		10 (4.2)
Rapid act. Insulin + long act. Insulin + Big + TZD		1 (0.4)
Rapid act. Insulin + long act. Insulin + AGI + SU		1 (0.4)
Rapid act. Insulin + long act. Insulin + AGI + TZD		1 (0.4)
70/30 Mix Insulin + AGI + Big		1 (0.4)
70/30 Mix Insulin + AGI + SU		4 (1.7)
70/30 Mix Insulin + SU + Big		2 (0.8)
70/30 Mix Insulin + Big + TZD		1 (0.4)
75/25 Mix Insulin + SU + Big		1 (0.4)
<b>Total</b>		<b>29 (12.1)</b>
<b>Type 8 combination</b> (Insulin Basal-Bolus + 3 OAD)	Rapid act. Insulin+long act. Insulin+AGI+Big+TZD	1 (0.4)
	<b>Total</b>	<b>1 (0.4)</b>
	<b>Total</b>	<b>240 (100.0)</b>

Note: Percentage to total patients (240 patient)

SU: sulphonyl urea (Glimepiride, Gliclazide, Gliquidone), AGI: alpha glycosidase inhibitor (acarbose), Big: biguanide (metformin), TZD: Thiazolidindione (pioglitazon), Long act. Insulin (glargin, detemir), Rapid act. Insulin (aspart, glulisine), 70/30 Mix insulin (Protamin aspart/aspart), 75/25 Mix insulin (Protamin lispro/lispro)



Tabel VII. Post prandial blood glucose (2PPBG) and bolusi insulin adjustment (Rapid acting Insulin)

2PPBG(mg/dL)	Dose Adjustment	Number of Patients (%)	Total Patients (%)
<100	Dose reduce	1(1.10)	3(3.3)
	No change	2(2.20)	
100-199	No change	26(28.57)	32(35.2)
	Dose reduce	6(1.10)	
200-299	Dose reduce	1(1.10)	34(37.4)
	No Change	20(21.98)	
	Dose Increase	13(7.69)	
300-399	No Change	7(7.69)	15(16.5)
	Dose increase	8(3.30)	
400-499	No change	1(1.10)	5(5.5)
	Dose increase	4(2.20)	
500-599	Dose increase	2(1.10)	2(2.2)

Note: Total patient = 91 with 2PPBG

Tabel VIII. Blood glucose achievement

	Blood Glucose Level*	Number of Patients	Total (%)
Achieved the target	Hypoglycemia** (GDP <80mg/dL)	9	9 (4.1)
	- FBG 80-130mg/dL	46	46 (20.8)
	- 2PPBG <180mg/dL		
Not Achieved the Target	- RBG < 200mg/Dl	110	
	- FBG >130 mg/dL		
	- 2PPBG >180mg/dL		
FBG achieved	- RBG ≥200mg/dL	37	166 (75.1)
	- FBG 80-130mg/dL		
	- 2PP BG Not Achieved		
FBG Not Achieved	- 2PPBG >180mg/dL	19	
	- FBG>130mg/dL		
	- 2PPBG Achieved		
	- 2PPBG <180mg/dL		
	<b>Total</b>	<b>221</b>	<b>(100.00)</b>

Note: BG achievement was outcome of achievement one month therapy before; Total patient 221, there is no BG data in 19 patient; (\*) ADA, 2015; (\*\*) Hypoglycemia is indicated by FBG <80mg/dL (PERMENKES No. 5 Tahun 2014).

It can be seen that the dose of insulin therapy is highly individual, due to the sensitivity of insulin receptors in each individual is different, the varying action of insulin in each individual (Boucher *et al.*, 2014).

The oral antidiabetic (OAD) used in this study were sulfonylureas (gliclazides, glimepirides, gliquidones), biguanides (metformin),  $\alpha$ -glucosidase (acarbose) and thiazolidinedione (pioglitazone) inhibitors. In this study, 37.1% of patients received sulfonylurea therapy, i.e. glimepiride (29.2%), gliclazide (4.2%), and gliquidone (3.8%). The

UKPDS study showed that more than 50% of DM patients receiving sulfonylurea therapy required additional insulin therapy to achieve the glycemic target (Massi and Orsini, 2008). The combination of glimepiride with insulin can lower uncontrolled blood glucose levels (Funk, 2014). However, in the combination of insulin and sulfonylurea, patient's blood glucose levels should be monitored, considering that both drugs are synergistic in lowering blood glucose levels, which can increase the risk of hypoglycemia (Raccab *et al.*, 2007).

In this study, 42.5% of patients received metformin therapy. Metformin is recommended as first-line therapy for Type 2 diabetes, because it increases insulin sensitivity and not increase weight or cause hypoglycemia. Beside that metformin has lowering effect on cholesterol, free fatty acids and triglycerides, so that improved lipid profiles and inhibit the occurrence of macrovascular and microvascular complications (Hundal and Inzucchi, 2003), but this drug is contraindicated in patients with renal impairment, liver disease, hypoxia, and a history of lactic acidosis (Kroon and Williams, 2013). A total of 20.4% of patients received acarbose, an oral antidiabetic that acts by inhibiting the  $\alpha$ -glucosidase enzyme found in the small intestine wall, reduces postprandial glucose levels in Type 2 DM patients (Schwinghammer, 2015). This drug has a low risk of hypoglycemia (Li Feng-fei *et al.*, 2015). A total of 7.1% of patients received pioglitazone, that has effect in lowering insulin resistance by increasing the amount of glucose transporter. In patients with type 2 DM with dyslipidemia, a thiazolidinedione can improve lipid profile. Research conducted by Ghazzi showed that thiazolidinedione (pioglitazone) decrease triglyceride levels and increase HDL levels in Type 2 DM patients. However, the influence of thiazolidinedione on lipids is not enough to replace statins as dyslipidemia therapy (Ismail, 2004).

Several studies have shown that intensive glycemic control can be achieved by combination therapy (Massi and Orsini, 2008). It has been stated that combination of insulin and OAD results better in glycemic control compared to single insulin use (Pranoto, 2011). The advantage of this combination can reduce the required dose of insulin, decrease the number of injections, ease insulin dose titration and improve adherence (Massi and Orsini, 2008).

In this study, 30.8% of patients received insulin therapy (single or basal-bolus) and 69.2% of patients receiving OAD-insulin combination therapy. The combination of insulin-OAD therapy is very diverse, ranging from a combination of 1-2 of insulin types and 1-4 of oral antidiabetic (Table 5). Basal-bolus therapy is given when blood glucose and HbA1C levels were still uncontrolled with

combination therapy of basal insulin and OAD (Harper *et al.*, 2013), the addition of prandial insulin improves overall glycemic control (Umpierrez *et al.*, 2007). Prandial insulin is given at an initial dose of 6U or 0.1/kgBW and administered before each meal.

In this study, it was found that several inappropriate combinations of therapy were not in accordance with the protocol, such as the combination of rapid-acting insulin (bolus insulin) with sulfonylurea groups, which may increase the risk of hypoglycemia. Oral insulin secretagogin (sulfonylurea) should be discontinued if prandial insulin is given (Raccach *et al.*, 2007; Pranoto, 2012). In addition, there was an inappropriate combination of long-acting insulin with 4 types of oral antidiabetic (Type 4 Combination). This combination was not appropriate. According to PERKENI, if the patients receive the combination therapy of basal insulin and OAD but the blood glucose is still uncontrolled, then the therapy has to stop and shift to insulin intensively (basal-bolus therapy) (PERKENI, 2011). It is in line with the recommendation of the American Diabetes Association, if the patient's HbA1C target is not achieved for 3 months with triple therapy or combination of basal insulin and 2 OAD, it is recommended to switch to basal-bolus therapy (ADA, 2015).

The dosage and frequency of antidiabetic use in type 2 diabetes mellitus therapy are highly dependent on patient's condition that includes blood glucose level, HbA1C value, complication and comorbid, and patient compliance. Blood glucose levels (FBG and 2PPBG) are indicators of patient glycemic level controls. Dose adjustment of long-acting insulin was based on FBG, while rapid-acting insulin dose is adjusted to 2PPBG (ADA, 2015). In Table VI showed the value patient's fasting blood glucose (FBG) levels and its basal insulin therapy. Patients with FBG <70 mg/dL (2.3%) had hypoglycemic conditions, so it was recommended to decrease the insulin dose by 2-4U (Nathan, 2009). Patients with FBG 70-130 mg/dL (37.8%) is recommended to maintain the dose, but in this study there was an increase insulin dose by 2-6 U, this was due to blood glucose levels still reaches the upper limit of the glycemic target and the patient has



a high 2PPBG level. The addition of a basal insulin dose may be lowering the patient's 2PPBG levels (Rakel *et al.*, 2015). In some patients there was a dose reduction of 2-8 U because the patient has a risk of hypoglycemia or experienced hypoglycemia. Patients with GDP >130 mg/dL (30%) and GDP >180 mg/dL (30%) were recommended for the addition of 2-4U insulin, but 31.3% of patients with high GDP levels were not added insulin because there is significant BG decrease from previous therapy. The similar reason use for insulin adjustment 2PPBG.

Many aspects must be considered in determining the patient's glycemic target. The recommended glycemic target by the American Association Diabetes is the optimal target, but the glycemic target is individualized and tailored to the needs of each patient (ADA, 2015). Factors to be considered for the determination of glycemic targets in patients with type 2 diabetes include age or life expectancy, comorbidity, duration of diabetes, the risk of hypoglycemia, and presence of microvascular complications (ADA, 2015).

Blood glucose target is achieved if FBG is in the range 80-130 mg/dL and 2PPBG <180 mg/dL (ADA, 2015). This study showed of 240 patients with Type 2 DM there were 19 patients who did not have blood glucose levels at the time of observation, so that the blood glucose level was obtained from 221 patients. Of the 221 patients, 20.8% patients achieved BG target, while 75.1% patients did not achieve blood glucose target. It showed that blood glucose controlled in these patients is not easy. These patients were referral patients from first health services, sent to hospital as higher second health services cause they had uncontrolled blood glucose or had DM complication. As blood glucose or complication has been controlled this patients would be referred back to first health services. Previous study in type 2 DM geriatric patients showed blood glucose target was achieved in 53% patients (Suprapti *et al.*, 2014).

A total of 4.1% of patients had hypoglycemic conditions, characterized by FBG level <80 mg/dL. According to the ADA, the condition of hypoglycemia is characterized by blood glucose levels <70 mg/dL, but criteria for hypoglycemia in the clinic is characterized

by blood glucose <80 mg/dL, this is done because the hypoglycemia condition is dangerous and life-threatening, so that higher values are used for the purpose of patient safety. It also complies with PERMENKES No.5, 2014 on the Clinical Practice Guidelines for Physicians, which explains that hypoglycemia is characterized by blood glucose levels <80 mg/dL (PERMENKES RI, 2014).

Side effects of insulin found in this study were hypoglycemia. A total of 6.7% of patients had hypoglycemia and were identified to receive insulin or sulfonylurea therapy. Potential side effects of insulin and sulfonylurea use are hypoglycemia (Kennedy & Masharani, 2015). Hypoglycemia is shown in the presence of complaints such as shaking, cold sweat, dizziness, weakness and palpitations. Patients with hypoglycemia usually result from overly high doses of insulin, inadequate dietary intake (delayed, skipped meal, little intake), fasting conditions, excessive activity. Other DRP found were an inappropriate combination, i.e. the combination of rapid-acting insulin with sulfonylurea group OAD (3.8%), and a combination of 1 insulin with 4 OAD (0,4%).

## CONCLUSION

In conclusion insulin therapies were complicated and individually, most of the patients still did not reach the target and there was potential drug related problem in this patients group. So that caring from solid interprofesional health collaboration is needed.

## ACKNOWLEDGEMENT

We are grateful to Universitas Airlangga Teaching Hospital for permission doing this research.

## REFERENCES

- American Diabetes Association., 2015. Standards of Medical Care in Diabetes: Volume 38 Supplement 1: S1-S83
- Barret KE., Barman SM., Boitano S., Brooks HL. 2012. Ganong's Review of Medical Physiology. 24th Edition. New York: The McGraw-Hill Companies.
- Bennett K., Bhandari., 2015. An overview of diabetic nephropathy: Epidemiology, pathophysiology and treatment. *J Diabetes Nursing*, 19: 2: 61-67



- Bloomgarden TZ., 2004. Type 2 Diabetes in the Young: The evolving epidemic. *Diabetes Care*. 27: 4. pp. 998
- Boucher J., Kleinridders A., Kahn C. Ronald., 2014. Insulin Receptor Signaling in Normal and Insulin-Resistant States. Harvard Medical School
- CDC. 2015. Distribution of Age at Diagnosis of Diabetes Among Adult Incident Cases Aged 18-79 Years. *Centers for Disease Control and Prevention*
- Funk JL. 2014. Disorder of The Endocrine Pancreas. In: McPhee.S. J; Hammer G.D. (Eds.), *Pathophysiology of Disease an Introduction to Clinical Medicine*. 7th ed. : New York : Mc Graw Hill
- Harper W., Clement M., Goldenberg R., Hanna A., Main A., et al., 2013. Pharmacologic Management of Type 2 Diabetes. *Can. J.Diabetes*. 37(2013): S61-S68
- Hundal, R.S., Inzucchi, S.E., 2003. Metformin: New Understandings, New Uses. Leading Article. pp 1800-1889
- IDF Diabetes Atlas. 2013. International Diabetes Federation 6th ed. pp: 19-99
- Inzucchi SE., Bergenstal RM., Ferrannini E., Nauck M., Peters AL., et al., 2015. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient Center Approach. *Diabetes Care* 2015; 38: 140-149
- Ismail F., 2004. Current Management of Type 2 Diabetes: Why Thiazolidinediones Should Be the Cornerstone of Therapy. *The J. Applied Research*. Volume. 4, No 3.
- Kennedy and Masharani. 2012. Pancreatic Hormones and Antidiabetic Drugs. In: Basic and Clinical Pharmacology. 12th Edition. New York: The McGraw-Hill Companies, p. 743-765.
- Kirkman MS., Jones VB., Clark, N., Florez H., Haas, LB., et al 2012. Diabetes in Older Adults. *Diabetes Care*, V35. 2650-2655
- Kroon and Williams. 2013. Endocrine Disorders. In: Koda-Kimble & Young's (Eds.). Applied Therapeutics the Clinical Use of Drugs.10th ed. *Wolters Kluwer Health: Lippincott Williams & Wilkins*.
- Kyung BK., Roh E., Seul YY., Kyong MM., 2016. Difference between old and young adults in contribution of  $\beta$ -cell function and sarcopenia in developing diabetes mellitus. Original Article: *J Diabetes Investigation*, Volume 7, No.2, pp 233-238
- Massi MB., Orsini MF., 2008. Treatment of Type 2 Diabetes with Combined Therapy. *Diabetes Care*, Volume 31, Supplement 2.
- Meneghini LF., 2009. Early Insulin Treatment in Type 2 Diabetes. *Diabetes Care*. 32:2: S266-S269
- Nathan DM. Buse JB. Davidson MB., Ferrannini E. Holman RR., et al., 2009. Medical Management of Hyperglycemia in Type 2 Diabetes: *A Consensus Algorithm for the initiation and Adjustment of Therapy*, Vol 32. No.1. pp 193-203
- Ndraha S. 2014. *Medicinus : Diabetes Melitus Tipe 2 dan TataLaksana Terkini* Vol 27 No.2 . Jakarta
- PERKENI. 2011. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia. Pengurus Besar Perkumpulan Endokrinologi Indonesia.
- Pranoto A., 2011. Insulin Therapy for Type 2 Diabetes Early Insulination: Rationale & Evidence. *Pusat Diabetes & amp*
- Pranoto A. 2012. Terapi Insulin: Pada Penderita Diabetes Melitus Rawat Jalan dan Rawat Inap. Surabaya: Airlangga University Press.
- Raccab D., Bretzel RG., Owens D., Riddle M., 2007. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? *Diabetes Metab Res Rev* 23(4):257-264
- RISKESDAS., 2013. Riset Kesehatan Dasar, Jakarta: Balitbang Kementerian Kesehatan Republik Indonesia.
- Rismayanthi Cerika. 2010. Medikora : Terapi Insulin Sebagai Alternatif Pengobatan Bagi Penderita Diabetes : Vol VI, No. 2. Yogyakarta
- Schwinghammer TL. 2015. Endocrinologic Disorders. In: Dipiro, J. T. Pharmacotherapy: A Pathophysiologic Approach. 7th Ed.: New York, McGraw-Hill Medical. pp 155- 175.
- Soewondo P., Soegondo S., Suastika K., Pranoto A., Soeatmadji D.W., Tjokroprawiro A. 2010. The DiabCare Asia 2008 study – *Outcomes on control and complications of type 2 diabetic patients in Indonesia* Vol.19, No 4.



- Suastika K., Soeatmadji DW., Asdic., Adam MF., Soegondo S., *et al.*, 2011. *Petunjuk Praktis Terapi Insulin*. pp. 1-35
- Suprapti B., Vilaningtyas N., Nilamsasri WP, Ichwani J., 2014. Lood glucose target achievement and antidiabetes regimen in Type-2 Diabetes Geriatric Patients. *Indonesian J. Pharm*, Vol. 25:2, pp. 98-104.
- Tanwani LK. 2011. Insulin Therapy in the Elderly Patient with Diabetes. *The Am J Geriatric Pharmacotherapy*. Louisville, Kentucky. pp 24-33.
- Tanyolac S., Goldfine, ID., Kroon L. 2010. Insulin-Pharmacology, Types of Regimens, and Adjustment. San Fransisco: *University of California*.
- Umpierrez G., Smiley D., Zisman A., Prieto LM., *et al.*, 2007. Original Article: Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patient with Type 2 Diabetes (Rabbit 2 Trial). *Diabetes Care*. 30: 9, pp. 2181-2185
- World Health Organization. 2016. Diabetes World Health Organization. Geneva: World Health Organization.



Home > About the Journal > **Editorial Team**

## Editorial Team

### Editor in Chief

Prof. Sugiyanto Sugiyanto, Universitas Gadjah Mada, Department of Pharmacology and Clinical Pharmacy, Indonesia

### Editorial Board

Prof. Dr. Abdul Rohman, Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Gadjah Mada, Indonesia  
 Prof. Dr. Shufeng Zhou, Department of Pharmaceutical Sciences, University of South Florida Tampa, United States  
 Prof. Dr. Kazutaka Maeyama, Ehime University, Department of Pharmacology, Japan  
 Prof. Dr. Masashi Kawaichi, Nara Institute of Science and Technology, Division of Gene Function in Animals, Japan  
 Prof. Dr. Gunawan Indrayanto, Universitas Airlangga, Faculty of Pharmacy, Indonesia  
 Prof. Dr. Veeresh P. Veerapur, Sree Siddaganga College of Pharmacy, Pharmaceutical Chemistry Department, India  
 Prof. Dr. Agung Endro Nugroho, Universitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Indonesia  
 Prof. Dr. Lee E. Kirsch, University of Iowa, Division of Pharmaceutics and Translational Therapeutics, United States  
 Prof. Dr. Henk Timmerman, Vrije Universiteit Amsterdam, Division of Medicinal Chemistry, Netherlands  
 Prof. Dr. Jeroen Kool, Vrije Universiteit Amsterdam, Division of BioAnalytical Chemistry, Netherlands  
 Dr. Saikat Kumar Basu, University of Lethbridge, Department of Biological Sciences, Canada  
 Dr. Joseph David Francis Tucci, La Trobe University, School of Pharmacy and Applied Science, Australia  
 Dr. Chuda Chittasupho, Srinakharinwirot University, Department of Pharmaceutical Technology, Thailand  
 Dr. Rina Kuswahyuning, Universitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmaceutics, Indonesia  
 Dr. Supang Khonde, University of Phayao, School of Pharmaceutical Sciences, Thailand  
 Dr. Pudjono Pudjono, Universitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Indonesia  
 Dr. Montarat Thavorncharoensap, Faculty of Pharmacy, Department of Pharmacy, Mahidol University, Thailand  
 Dr. Karuna Shanker, Central Institute of Medicinal and Aromatic Plants India, Department of Analytical Chemistry, India  
 Dr. Jun An, Sun Yat-Sen University, Department of Cardiothoracic Surgery, China  
 Dr. Mohammed Emamussalehin Choudhury, Department of Pharmacology, Bangladesh Agriculture University, Bangladesh  
 Dr. Abdul Wahab, Department of Pharmacy, Kohat University of Science and Technology (KUST), Pakistan  
 Dr. Tony Hadibarata, Curtin University Sarawak Malaysia, Department of Environmental Engineering, Malaysia  
 Dr. Shahin Gavanji, Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, Iran, Islamic Republic of

### Indonesian J Pharm indexed by:



[indonesianjpharm.farmasi.ugm.ac.id/index.php/3/about/editorialTeam](http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/about/editorialTeam)

[Focus & Scope](#)

[Author Guideline](#)

[Author Fees](#)

[Online Submission](#)

[Editorial Board](#)

[Peer Reviewer](#)

[Subscription Form](#)

[Screening for Plagiarism](#)

[Visitor Statistics](#)

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI




### CITATION ANALYSIS

- ▶ SCOPUS
- ▶ GOOGLE SCOLAR

### TEMPLATE



### TOOLS



### NOTIFICATIONS

- ▶ View
- ▶ Subscribe

### USER



## Trading dan ikuti kontes Finex

Trading di Finex selama kontes untuk mendapatkannya. Jumlah iPhone 11 Pro tak terbatas

Finex

OPEN

# Indonesian Journal of Pharmacy

<b>Country</b>	Indonesia -  SIR Ranking of Indonesia
<b>Subject Area and Category</b>	Health Professions Pharmacy  Medicine Pharmacology (medical)  Pharmacology, Toxicology and Pharmaceutics Pharmaceutical Science
<b>Publisher</b>	Universitas Gadjah Mada - Faculty of Pharmacy
<b>Publication type</b>	Journals
<b>ISSN</b>	23389486, 23389427
<b>Coverage</b>	2018-ongoing

# 1

H Index

**Scope** The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: - Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.



[Homepage](#)

[How to publish in this journal](#)

[Contact](#)



[Join the conversation about this journal](#)







## International Symposium 2020

international journal indexed by Scopus, Wos, Esci, Doaj, Google Scholar, Copernicus, etc

Isasem.com

OPEN

no data



Indonesian Journal of  
Pharmacy

Not yet assigned  
quartile

SJR 2018

0

powered by scimagojr.com

← Show this widget in  
your own website

Just copy the code below  
and paste within your html  
code:

```
<a href="https://www.scima
```

## International Symposium 2020

international journal indexed by Scopus, Wos, Esci, Doaj, Google Scholar, Copernicus, etc

isasem.com

OPEN





SJR

Scimago Journal &amp; Country Rank

Enter Journal Title, ISSN or Publisher Name

[Home](#)[Journal Rankings](#)[Country Rankings](#)[Viz Tools](#)[Help](#)[About Us](#)

# Indonesian Journal of Pharmacy

<b>Country</b>	Indonesia -  SJR Ranking of Indonesia
<b>Subject Area and Category</b>	Health Professions Pharmacy  Medicine Pharmacology (medical)  Pharmacology, Toxicology and Pharmaceutics Pharmaceutical Science
<b>Publisher</b>	Universitas Gadjah Mada - Faculty of Pharmacy
<b>Publication type</b>	Journals
<b>ISSN</b>	23389486, 23389427
<b>Coverage</b>	2016-2019

# 5

H Index


**Scope** The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.

[Homepage](#)[How to publish in this journal](#)[Contact](#)[Join the conversation about this journal](#)


Quartiles




Quartiles




SJR



Citations per document




Total Cites Self-Cites




- Cites / Doc. (4 years)
- Cites / Doc. (3 years)
- Cites / Doc. (2 years)

External Cites per Doc Cites per Doc



% International Collaboration



Citable documents Non-citable documents

Cited documents Uncited documents



100

100

Indonesian Journal of Pharmacy



Pharmaceutical Science

SJR 2019 0.14

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" data-bbox="309 237 484 251">
```

**N** Niar 2 months ago

Why this journal not yet assigned quartile ?

reply

SCImago Team



**Melanie Ortiz** 2 months ago

Dear Niar,

Thank you for contacting us. Our data come from Scopus, they annually send us an update of the data. This update is sent to us around April / May every year. Thus, the indicators for 2019 will be available in June 2020. Best Regards, SCImago Team

**F** faridatulain 9 months ago

i like this jurnal

reply

SCImago Team



**Melanie Ortiz** 9 months ago

Dear user, thanks for your participation! Best Regards, SCImago Team

## Re: Fwd: Galley Proof 28 No 4, 2017

---

Dari: Budi Suprapti (budiprapti@yahoo.co.id)

Kepada: mfi@ugm.ac.id; mfi.ugm@gmail.com

Tanggal: Senin, 5 Maret 2018 03.28 WIB

---

Dear Editor of Indonesian Journal of Pharmacy.

Thank you for the acceptance of my paper. For these I have attached:

1. Copyright assignment form
2. Revision of my paper in page 9, we try to explain the low achievement of blood glucose target in these patients group.

Regards,

Budi Suprapti

*Clinical Pharmacy Dept*

*Faculty of pharmacy Universitas Airlangga*

*Jalan Darmawangsa Dalam Surabaya;*

*Hospital Pharmacy Dept.*

*Universitas Airlangga Hospital*

*Jalan Mulyorejo Surabaya.*

---

Pada Rabu, 28 Februari 2018 09.10.34 WIB, Majalah Farmasi Indonesia <mfi@ugm.ac.id> menulis:

Dear Budi Suprapti,

Your manuscript has been accepted for publication in Indonesian Journal of Pharmacy (attached 1). On behalf of Editorial team, we are looking forward to receiving your new paper. Please sign the copyright transfer (attached 2) in order to allow me to process your manuscript. Please check the proof (attached 3) carefully and if you need revision you can write in file (attached 4).

Your revised manuscript and Copyright Form must be returned to us within 5 days (March 5, 2018). Please refer to the attached documents below.

Sincerely,

Editorial Staff



2. Copyright form (Budi Suprapti)-MFI.pdf

924.2kB



4. Budi.docx

123.4kB



## Fwd: Galley Proof 28 No 4, 2017

---

Dari: Majalah Farmasi Indonesia (mfi@ugm.ac.id)

Kepada: budiprapti@yahoo.co.id

Tanggal: Rabu, 28 Februari 2018 09.10 WIB

---

Dear Budi Suprpti,

Your manuscript has been accepted for publication in Indonesian Journal of Pharmacy (attached 1). On behalf of Editorial team, we are looking forward to receiving your new paper. Please sign the copyright transfer (attached 2) in order to allow me to process your manuscript. Please check the proof (attached 3) carefully and if you need revision you can write in file (attached 4).

Your revised manuscript and Copyright Form must be returned to us within 5 days (March 5, 2018). Please refer to the attached documents below.

Sincerely,

Editorial Staff



1. LOA.pdf  
425.2kB



2. Copyright form - MFI.doc  
30kB



3. Galley Proof (Budi Suprpti).pdf  
953kB



4. Budi.docx  
129.4kB

## Insulin Publication - ICPAPS

---

Dari: Budi Suprapti (budiprapti@yahoo.co.id)

Kepada: mfi@ugm.ac.id

Tanggal: Jumat, 27 Oktober 2017 04.44 WIB

---

Dear MFI Editor,

I have informed from ICPAPS scientific committee that my manuscript paper entitled "Review of Insulin Therapy In Type 2 Diabetes Mellitus Ambulatory Patients" has passed initial screening for potential publication in Indonesian Journal of Pharmacy.

I have attached the above committee announcement and we wait the information for further publication .

Thank you

Regards

Budi Suprapti

*Dept.of Clinival Pharmacy*

*Faculty of Pharmacy, Universitas Airlangga*

*Kampus B Universitas Airlangga Jln. Darmawangsa Dalam.*

*Department of Pharmacy*

*Universitas Airlangga Teaching Hospital*

*Kampus C Universitas Airlangga Jln. Mulyoredjo*

*Surabaya, Indonesia*



Budi Suprapti INSULIN(MFI).pdf

609.3kB